• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Novocure touts long-term analysis of Optune drug-device combo

September 12, 2016 By Sarah Faulkner

NovoCure touts long-term analysis of OptuneNovocure (NSDQ: NVCR) touted a long-term analysis of data from a Phase III pivotal trial of its Optune device in combination with temozolomide for the treatment of newly-formed glioblastomas.

Survival data for nearly 700 patients confirmed interim results from the trial, 1st published in December 2015 in the Journal of the American Medical Assn. Patients treated with Optune plus temozolomide had superior 2-, 3- and 4-year survival rates compared to patients treated with temozolomide alone.

The results come weeks after the St. Helier, N.J.-based company announced that Optune, in combination with placlitaxel, is effective against ovarian cancer.

Optune is a noninvasive, portable device that emits targeted tumor fields (TTFields), which are designed to selectively disrupt the cell division process in cancer cells. Novocure won FDA approval in July for the Optune device to treat GBM.

The results of the long-term analysis will be presented as a late-breaking oral presentation in November at the 21st Annual Scientific Meeting of the Society for Neuro-Oncology in Scottsdale, Arizona.

“The analysis of the mature dataset provides an impressive confirmation of the improvement in both progression free and overall survival we saw in the trial’s interim analysis results, and demonstrates the trial met its pre-specified endpoints at both interim and long-term analyses,” principal investigator Dr. Roger Stupp, professor at the University of Zurich and director of the department of oncology at the Zurich University Hospital, said in prepared remarks. “I look forward to sharing the data with the scientific community in November.”

The company’s stock was up 7.79% to $8.72 apiece in mid-afternoon activity.

Don’t miss Novocure chairman Bill Doyle at this year’s DeviceTalks Boston event, Wed., Sept. 28. Tickets are still available here.

Filed Under: Clinical Trials, Drug-Device Combinations, Radiosurgery Tagged With: NovoCure

IN CASE YOU MISSED IT

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS